SCDM REGULATORY COUNCIL

Fostering collaboration
between industry and
regulatory authorities

SCDM Regulatory Council

The SCDM Regulatory Council (SRC) brings together industry and regulatory authorities in an open dialogue to identify areas of collaboration, and to enhance knowledge and awareness of how the current industry best practice aligns with regulations.

SRC structure

The SCDM Regulatory Council is set to welcome representatives from regulatory organizations worldwide alongside the SCDM Executive Committee and the SCDM Community Engagement Board liaison – who serves as the Council Chair. Currently, regulatory representatives from the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) are official members of our Regulatory Council, under the principles of a Public-Private Partnership.

MEET THE REGULATORS

SCDM Regulatory Council

The Council meets monthly in a virtual setting to advance its mission. Minutes from the meetings are publicly available.

SCDM CHAIR 2024
Patrick Nadolny
Global Head, Clinical Data Management
Sanofi
SCDM VICE CHAIR 2024
Carol Schaffer
Director, Program Lead in the Vaccines therapeutic area, Clinical Data Sciences department
Pfizer
SCDM TREASURER
Jonathan Andrus
President & COO
CRIO
SCDM PAST CHAIR
Arshad Mohammed
Head of Data Management
GSK
REGULATOR
Cheryl Grandinetti, PharmD
Associate Director for Clinical Policy
Division of Clinical Compliance Evaluation | Office of Scientific Investigations | Office of Compliance | CDER | FDA
REGULATOR
Elizabeth Kunkoski
Health Science Policy Analyst
Center for Drug Evaluation and Research (CDER) | Office of Medical Policy (OMP) | FDA
SCDM REGULATORY TOWNHALLS

A platform for senior-level peer-to-peer exchanges

An unmissable and highly popular session during many of the SCDM conferences, the Regulatory Townhall brings together regulators from the US and across Europe in an engaging discussion moderated by Jonathan Andrus, SCDM Treasurer. In case you missed some of our past conferences, you can access all Regulatory Townhall discussions on-demand on the SCDM Learning Hub.

FDA GUIDANCE REVIEWS

FDA CDER Guidances relevant to the CDM profession

At SCDM, we work closely with our members to provide feedback on FDA CDER guidances that are most relevant and applicable to the Clinical Data Management profession. From the 2024 CDER Guidance Agenda, we have identified the guidance below as CDM-relevant.

CATEGORIES
  • Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
  • Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drugs and Biological Products
  • Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products
  • E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports
  • E6(R3) Good Clinical Practice Annex 2
  • E20 Adaptive Clinical Trials
  • M4Q(R2) Revision of M4Q(R1) CTD on Quality
  • M13B Bioquivalence for Additional Solid, Oral Dosage Strengths Including Biowaiver Considerations
  • M14 General Principles on Planning and Designing Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment
  • M15 MIDD General Principles
  • Q1/Q5C Targeted Revisions of ICH Stability Guidelines
  • Q3E Impurity: Assessment and Control of Extractables and Leachables for Pharmaceuticals and Biologics
  • Q5A(R2) Biotechnology Products Derived from Cell Lines of Human or Animal Origin
CDER Center for Clinical Trial Innovation (C3TI)

Innovative approaches to clinical trials

In alignment with SCDM’s goal of promoting cooperation between industry and regulatory authorities, we’re delighted to share more details on the CDER Center for Clinical Trial Innovation (C3TI). Established in April 2024 by CDER to enable and amplify innovative approaches to clinical trials that are designed to improve the efficiency and effectiveness of drug development, C3TI serves as a central hub to:

Facilitate coordination across CDER innovation programs to more easily engage in cross-program and cross-center collaborations.

Manage a demonstration program that will expand opportunities for sponsors of innovative clinical trials to interact with CDER staff and for these trials to serve as case examples to spur further innovation.

Provide CDER staff, drug developers, and other interested parties with a single CDER point of contact to assist with non-product-specific questions related to clinical trial innovation.

Support knowledge sharing through various mechanisms.